Lung cancer is the leading cause of cancer death in the United States, claiming more lives each year than breast, colorectal, and prostate cancers combined. In 2024, the American Cancer Society estimated approximately 234,580 new lung cancer diagnoses and 125,070 deaths. Yet the landscape of lung cancer treatment has transformed dramatically in the past decade — targeted therapies, immunotherapy, and improved screening are changing survival statistics in ways that would have seemed impossible a generation ago. Understanding your risk, recognizing early symptoms, and knowing the current treatment options can meaningfully improve outcomes. For an overview of major health conditions, visit our medical conditions guide.
Types of Lung Cancer
Non-Small Cell Lung Cancer (NSCLC)
NSCLC accounts for approximately 80 to 85 percent of all lung cancers. It includes three major subtypes. Adenocarcinoma, the most common, typically arises in the outer regions of the lung and is the type most frequently seen in non-smokers and younger patients. Squamous cell carcinoma tends to develop in the central airways and is strongly associated with smoking. Large cell carcinoma can appear anywhere in the lung and tends to grow and spread quickly. These subtypes matter because they respond differently to treatment and may harbor distinct genetic mutations that can be targeted with precision therapies.
Small Cell Lung Cancer (SCLC)
SCLC accounts for 10 to 15 percent of lung cancers and is almost exclusively caused by smoking. According to the National Cancer Institute, SCLC is the more aggressive form — it grows rapidly, spreads early, and is frequently diagnosed after it has already metastasized. It is initially very responsive to chemotherapy and radiation, but recurrence is common. SCLC is staged simply as “limited stage” (confined to one side of the chest) or “extensive stage” (spread beyond one hemithorax).
Other Types
Less common lung malignancies include carcinoid tumors (slow-growing neuroendocrine tumors), lymphomas of the lung, and sarcomas. The lung is also a common site for metastases from cancers originating elsewhere — breast, colon, kidney, and melanoma frequently spread to the lungs. Distinguishing primary lung cancer from metastatic disease is critical for treatment planning.
Risk Factors
Cigarette smoking is responsible for approximately 80 to 90 percent of lung cancer deaths. The risk increases with the number of cigarettes smoked per day and the number of years of smoking, often quantified as “pack-years” (packs per day multiplied by years smoked). According to the CDC, smokers are 15 to 30 times more likely to develop lung cancer than non-smokers. Quitting reduces risk significantly over time, though it never returns to the level of a never-smoker.
Secondhand smoke exposure causes an estimated 7,300 lung cancer deaths per year among non-smokers in the United States. Radon — a naturally occurring radioactive gas that can accumulate in homes — is the second leading cause of lung cancer and the leading cause among non-smokers. The EPA estimates radon causes approximately 21,000 lung cancer deaths annually. Home radon testing is inexpensive and widely available.
Occupational exposures to asbestos, arsenic, chromium, nickel, and diesel exhaust are established risk factors. Air pollution, previous radiation therapy to the chest, and a personal or family history of lung cancer also increase risk. Notably, 10 to 20 percent of lung cancers occur in people who have never smoked — a reality that challenges the persistent stigma associating lung cancer exclusively with smoking.
Symptoms and Early Warning Signs
Lung cancer is notoriously difficult to detect early because the lungs have no pain receptors in their interior tissue, and early-stage tumors may produce no symptoms at all. When symptoms do appear, they often overlap with more common conditions, leading to delays in diagnosis. The Mayo Clinic identifies the following as common lung cancer symptoms: a new cough that doesn’t go away, changes in a chronic cough, coughing up blood (even a small amount), shortness of breath, chest pain that worsens with deep breathing or coughing, hoarseness, unexplained weight loss, bone pain, and headache.
Advanced lung cancer can cause a wide range of additional symptoms depending on where it has spread. Brain metastases may cause headaches, seizures, or neurological deficits. Bone metastases cause pain, often in the back, hips, or ribs. Liver metastases can cause jaundice and abdominal pain. Paraneoplastic syndromes — metabolic disturbances caused by substances produced by the tumor — can cause hypercalcemia, Cushing syndrome, or neurological problems.
When to seek emergency care: Call 911 or go to the nearest emergency room if you experience sudden severe shortness of breath, coughing up a significant amount of blood, sudden severe chest pain, confusion or sudden neurological changes, or signs of a blood clot (sudden leg swelling with difficulty breathing). These may indicate life-threatening complications of lung cancer.
Screening: Catching It Early
Low-dose computed tomography (LDCT) screening is the only proven method for early lung cancer detection and has been shown to reduce lung cancer mortality by 20 percent in the National Lung Screening Trial. The U.S. Preventive Services Task Force (USPSTF) recommends annual LDCT screening for adults aged 50 to 80 who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years.
Despite strong evidence supporting screening, uptake remains dismally low — only about 5 to 6 percent of eligible Americans get screened. Barriers include lack of awareness, provider failure to discuss screening, access issues, and concerns about cost and false positives. Under the Affordable Care Act, lung cancer screening is covered without cost-sharing for eligible individuals in most insurance plans, including Medicare.
Screening is not without limitations. False positives are common — most lung nodules found on LDCT are benign and require follow-up imaging, which can cause anxiety and additional testing. Overdiagnosis (finding cancers that would never have caused harm) is a concern, though it appears less significant than with some other cancer screenings. The benefits of screening outweigh these risks for the eligible population, but the decision should involve a shared discussion about the potential benefits, harms, and the individual’s preferences.
Staging
Staging determines how far the cancer has spread and is the most important factor in treatment planning and prognosis. NSCLC uses the TNM staging system: T describes the size and extent of the primary tumor, N describes spread to regional lymph nodes, and M indicates the presence or absence of distant metastasis. These are combined into overall stages I through IV.
Stage I lung cancer is confined to the lung without lymph node involvement. Stage II involves larger tumors or limited lymph node spread within the lung. Stage III indicates more extensive lymph node involvement, including mediastinal nodes. Stage IV means the cancer has spread to distant sites. The American Cancer Society reports 5-year survival rates that range from approximately 63 percent for stage I NSCLC to about 7 percent for stage IV — a stark illustration of why early detection matters.
Staging workup typically includes CT of the chest and abdomen, PET scan (which detects metabolic activity in cancer cells throughout the body), brain MRI (since lung cancer frequently metastasizes to the brain), and often invasive procedures such as mediastinoscopy or endobronchial ultrasound-guided biopsy to sample lymph nodes.
Treatment Options
Surgery
Surgery offers the best chance of cure for early-stage NSCLC (stages I and II and select stage III). The standard procedure is lobectomy — removal of the entire lobe containing the tumor. For smaller tumors or patients who cannot tolerate lobectomy, segmentectomy or wedge resection (removing a smaller portion of lung) may be performed. Recent data from the JCOG0802 trial showed that segmentectomy is non-inferior to lobectomy for small peripheral tumors, expanding options for lung-sparing surgery. Pneumonectomy (removal of an entire lung) is rarely performed today.
Radiation Therapy
Radiation therapy uses high-energy beams to destroy cancer cells. Stereotactic body radiation therapy (SBRT) delivers highly focused, high-dose radiation to small tumors in a few sessions and achieves local control rates comparable to surgery in early-stage patients who are not surgical candidates. Conventional radiation therapy is used for locally advanced disease, often combined with chemotherapy. Radiation also plays a role in palliating symptoms from metastatic disease, including brain metastases and bone pain.
Systemic Therapies
Chemotherapy remains a mainstay for advanced lung cancer, often using platinum-based doublets (cisplatin or carboplatin with a second agent). However, the real revolution has been in targeted therapy and immunotherapy. Molecular profiling of lung cancers — testing for mutations in EGFR, ALK, ROS1, BRAF, KRAS, and other genes — identifies patients who can benefit from targeted drugs that block specific cancer-driving pathways. For example, EGFR tyrosine kinase inhibitors (osimertinib) have transformed outcomes for patients with EGFR-mutant NSCLC.
Immunotherapy — particularly immune checkpoint inhibitors such as pembrolizumab, nivolumab, and atezolizumab — has become standard treatment for many lung cancer patients. These drugs release the brakes on the immune system, enabling it to recognize and attack cancer cells. According to the National Cancer Institute, immunotherapy has produced durable responses in some patients with advanced lung cancer, with a meaningful subset surviving five years or longer — outcomes that were exceptionally rare before these drugs became available.
Living With Lung Cancer: Support and Quality of Life
A lung cancer diagnosis impacts every dimension of life — physical, emotional, financial, and social. Integrating palliative care early in the treatment course has been shown to improve both quality of life and, in some studies, even survival. Palliative care is not the same as hospice; it focuses on symptom management, emotional support, and help with treatment decisions alongside curative-intent therapy.
Pulmonary rehabilitation, nutritional support, pain management, and psychological counseling are all important components of comprehensive lung cancer care. The financial burden can be substantial — understanding healthcare costs and insurance coverage for cancer treatment helps patients and families plan and access available resources, including patient assistance programs offered by pharmaceutical companies.
Support groups, both in-person and online, provide connection with others facing similar challenges. Organizations like the American Lung Association and LUNGevity Foundation offer resources, support networks, and advocacy for lung cancer patients and their families. Addressing the stigma that surrounds lung cancer — the assumption that patients “brought it on themselves” through smoking — is an ongoing effort that benefits all patients regardless of their smoking history.
Frequently Asked Questions
Can non-smokers get lung cancer?
Yes. Approximately 10 to 20 percent of lung cancers in the United States occur in people who have never smoked. Radon exposure, secondhand smoke, occupational carcinogens, air pollution, and genetic factors can all cause lung cancer in non-smokers. Lung cancer in never-smokers is more commonly adenocarcinoma and is more likely to harbor targetable genetic mutations like EGFR, which can be treated with effective targeted therapies.
What are the first signs of lung cancer?
Early lung cancer often has no symptoms, which is why screening is so important for high-risk individuals. When symptoms do appear, a persistent new cough, coughing up blood (even small amounts), unexplained shortness of breath, and unintentional weight loss are among the most common early presentations. Any cough lasting more than 2 to 3 weeks, particularly in a current or former smoker, warrants medical evaluation.
How effective is lung cancer screening?
The National Lung Screening Trial demonstrated a 20 percent reduction in lung cancer mortality with annual LDCT screening compared to chest X-ray. The NELSON trial in Europe showed an even larger benefit — a 24 percent reduction in lung cancer mortality among men. Screening is most effective when done consistently in the eligible population and followed by timely workup of abnormal findings. The main limitation is the high false-positive rate, which leads to additional imaging and, occasionally, unnecessary invasive procedures.
What is the survival rate for lung cancer?
Overall 5-year survival for lung cancer is approximately 25 percent — a figure that has been steadily improving thanks to earlier detection and better treatments. Stage-specific survival varies enormously: localized lung cancer (stage I) has a 5-year survival rate of about 63 percent, while distant (stage IV) disease has a rate of about 7 percent. Individual prognosis depends on many factors including stage, tumor biology, molecular markers, overall health, and response to treatment.
Is immunotherapy available for all lung cancer patients?
Not all patients are candidates for immunotherapy. Checkpoint inhibitors are most commonly used for advanced NSCLC, particularly tumors with high PD-L1 expression or those without targetable driver mutations. Some immunotherapy combinations are approved regardless of PD-L1 status. For SCLC, immunotherapy has been added to first-line chemotherapy. Patients with autoimmune conditions or those on immunosuppressive medications may not be suitable candidates. Molecular profiling of the tumor is essential to determine the best treatment approach.
What to Do Next
If you’re a current or former smoker aged 50 to 80 with a 20 pack-year history, ask your doctor about LDCT screening. This single conversation could save your life by catching cancer at a stage when cure is possible. If you’re currently smoking, quitting is still the most impactful thing you can do for your lung cancer risk — and your overall health. Effective cessation resources include the national quitline (1-800-QUIT-NOW), nicotine replacement therapy, and prescription medications like varenicline.
If you’ve been diagnosed with lung cancer, ensure that your tumor has undergone comprehensive molecular profiling. The specific mutations and biomarkers in your cancer can open doors to targeted therapies and immunotherapies that dramatically outperform traditional chemotherapy for many patients. Seek care at a center with experience in lung cancer — multidisciplinary tumor boards that include thoracic surgeons, medical oncologists, radiation oncologists, and pulmonologists provide the most informed treatment recommendations.
Lung cancer remains a formidable disease, but it is no longer the uniformly fatal diagnosis it once was. Advances in screening, molecular medicine, and immunotherapy are rewriting the story — and staying informed about your options is the first step toward the best possible outcome.